Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Combinazione di chemioterapia, Bevacizumab e/o Atezolizumab nel trattamento di pazienti con deficit di DNA Mismatch Repair Metastatico del colon-retto, lo studio COMMIT

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Studio sull'immunoterapia metastatica dMMR/MSI-H (COMMIT) del cancro del colon-retto: uno studio randomizzato di fase III sulla combinazione di mFOLFOX6/Bevacizumab/Atezolizumab rispetto al singolo agente Atezolizumab nel trattamento di prima linea di pazienti con deficit di riparazione del mismatch del DNA (dMMR)/microsatellite Cancro colorettale metastatico ad alta instabilità (MSI-H).

This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.

SECONDARY OBJECTIVES:

I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.

TRANSLATIONAL OBJECTIVE:

I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Kingman, Arizona, Stati Uniti, 86401
        • Kingman Regional Medical Center
    • Arkansas
      • Jonesboro, Arkansas, Stati Uniti, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Anaheim, California, Stati Uniti, 92806
        • Kaiser Permanente-Anaheim
      • Baldwin Park, California, Stati Uniti, 91706
        • Kaiser Permanente-Baldwin Park
      • Bellflower, California, Stati Uniti, 90706
        • Kaiser Permanente-Bellflower
      • Berkeley, California, Stati Uniti, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Concord, California, Stati Uniti, 94520
        • John Muir Medical Center-Concord
      • Fontana, California, Stati Uniti, 92335
        • Kaiser Permanente-Fontana
      • Harbor City, California, Stati Uniti, 90710
        • Kaiser Permanente South Bay
      • Irvine, California, Stati Uniti, 92618
        • Kaiser Permanente-Irvine
      • Los Angeles, California, Stati Uniti, 90027
        • Kaiser Permanente Los Angeles Medical Center
      • Los Angeles, California, Stati Uniti, 90034
        • Kaiser Permanente West Los Angeles
      • Marysville, California, Stati Uniti, 95901
        • Fremont - Rideout Cancer Center
      • Modesto, California, Stati Uniti, 95355
        • Memorial Medical Center
      • Ontario, California, Stati Uniti, 91761
        • Kaiser Permanente-Ontario
      • Orange, California, Stati Uniti, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Orange, California, Stati Uniti, 92868
        • Saint Joseph Hospital - Orange
      • Panorama City, California, Stati Uniti, 91402
        • Kaiser Permanente - Panorama City
      • Riverside, California, Stati Uniti, 92505
        • Kaiser Permanente-Riverside
      • Sacramento, California, Stati Uniti, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, Stati Uniti, 95817
        • University of California Davis Comprehensive Cancer Center
      • Salinas, California, Stati Uniti, 93901
        • Salinas Valley Memorial
      • San Diego, California, Stati Uniti, 92120
        • Kaiser Permanente-San Diego Zion
      • San Diego, California, Stati Uniti, 92108
        • Kaiser Permanente-Rio San Diego
      • San Marcos, California, Stati Uniti, 92078
        • Kaiser Permanente-San Marcos
      • Walnut Creek, California, Stati Uniti, 94598
        • John Muir Medical Center-Walnut Creek
      • Whittier, California, Stati Uniti, 90602
        • Presbyterian Intercommunity Hospital
      • Woodland Hills, California, Stati Uniti, 91367
        • Kaiser Permanente-Woodland Hills
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Aurora, Colorado, Stati Uniti, 80045
        • UCHealth University of Colorado Hospital
      • Boulder, Colorado, Stati Uniti, 80303
        • Boulder Community Foothills Hospital
      • Boulder, Colorado, Stati Uniti, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Colorado Springs, Colorado, Stati Uniti, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Stati Uniti, 80909
        • UCHealth Memorial Hospital Central
      • Colorado Springs, Colorado, Stati Uniti, 80920
        • Memorial Hospital North
      • Denver, Colorado, Stati Uniti, 80218
        • Rocky Mountain Cancer Centers-Midtown
      • Denver, Colorado, Stati Uniti, 80220
        • Rocky Mountain Cancer Centers-Rose
      • Denver, Colorado, Stati Uniti, 80204
        • Denver Health Medical Center
      • Denver, Colorado, Stati Uniti, 80206
        • National Jewish Health-Main Campus
      • Denver, Colorado, Stati Uniti, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, Stati Uniti, 80210
        • AdventHealth Porter
      • Englewood, Colorado, Stati Uniti, 80113
        • Mountain Blue Cancer Care Center - Swedish
      • Englewood, Colorado, Stati Uniti, 80113
        • Swedish Medical Center
      • Fort Collins, Colorado, Stati Uniti, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, Stati Uniti, 80528
        • Cancer Care and Hematology-Fort Collins
      • Golden, Colorado, Stati Uniti, 80401
        • National Jewish Health-Western Hematology Oncology
      • Greeley, Colorado, Stati Uniti, 80631
        • UCHealth Greeley Hospital
      • Greeley, Colorado, Stati Uniti, 80631
        • Banner North Colorado Medical Center
      • Littleton, Colorado, Stati Uniti, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Lone Tree, Colorado, Stati Uniti, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Loveland, Colorado, Stati Uniti, 80538
        • Medical Center of the Rockies
      • Loveland, Colorado, Stati Uniti, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Thornton, Colorado, Stati Uniti, 80260
        • National Jewish Health-Northern Hematology Oncology
      • Wheat Ridge, Colorado, Stati Uniti, 80401
        • Intermountain Health Lutheran Hospital
    • Connecticut
      • Danbury, Connecticut, Stati Uniti, 06810
        • Danbury Hospital
      • Hartford, Connecticut, Stati Uniti, 06102
        • Hartford Hospital
      • Meriden, Connecticut, Stati Uniti, 06451
        • Midstate Medical Center
      • New Britain, Connecticut, Stati Uniti, 06050
        • The Hospital of Central Connecticut
      • Norwich, Connecticut, Stati Uniti, 06360
        • William Backus Hospital
    • Delaware
      • Millville, Delaware, Stati Uniti, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, Stati Uniti, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Stati Uniti, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, Stati Uniti, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20002
        • Kaiser Permanente-Capitol Hill Medical Center
    • Florida
      • Fort Lauderdale, Florida, Stati Uniti, 33316
        • Broward Health Medical Center
      • Fort Myers, Florida, Stati Uniti, 33905
        • Regional Cancer Center-Lee Memorial Health System
      • Gainesville, Florida, Stati Uniti, 32610
        • UF Health Cancer Institute - Gainesville
      • Jacksonville, Florida, Stati Uniti, 32207
        • Baptist MD Anderson Cancer Center
      • Orlando, Florida, Stati Uniti, 32803
        • AdventHealth Orlando
    • Georgia
      • Albany, Georgia, Stati Uniti, 31701
        • Phoebe Putney Memorial Hospital
      • Athens, Georgia, Stati Uniti, 30607
        • University Cancer and Blood Center LLC
      • Augusta, Georgia, Stati Uniti, 30912
        • Augusta University Medical Center
      • Augusta, Georgia, Stati Uniti, 30901
        • Augusta Oncology Associates PC-D'Antignac
      • Augusta, Georgia, Stati Uniti, 30909
        • Augusta Oncology Associates PC-Wheeler
      • Newnan, Georgia, Stati Uniti, 30265
        • CTCA at Southeastern Regional Medical Center
    • Idaho
      • Boise, Idaho, Stati Uniti, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Stati Uniti, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Stati Uniti, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Stati Uniti, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Stati Uniti, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Stati Uniti, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Stati Uniti, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Stati Uniti, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Stati Uniti, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Stati Uniti, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Stati Uniti, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Bloomington, Illinois, Stati Uniti, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Stati Uniti, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, Stati Uniti, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Stati Uniti, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Stati Uniti, 60612
        • University of Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Stati Uniti, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Stati Uniti, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Stati Uniti, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Stati Uniti, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Stati Uniti, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Stati Uniti, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, Stati Uniti, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Stati Uniti, 61401
        • Illinois CancerCare-Galesburg
      • Glenview, Illinois, Stati Uniti, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park, Illinois, Stati Uniti, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Kewanee, Illinois, Stati Uniti, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Stati Uniti, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Stati Uniti, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Maywood, Illinois, Stati Uniti, 60153
        • Loyola University Medical Center
      • Mount Vernon, Illinois, Stati Uniti, 62864
        • SSM Health Good Samaritan
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Cancer Care Center of O'Fallon
      • Ottawa, Illinois, Stati Uniti, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Stati Uniti, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Stati Uniti, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Stati Uniti, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, Stati Uniti, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Stati Uniti, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Stati Uniti, 62702
        • Springfield Clinic
      • Urbana, Illinois, Stati Uniti, 61801
        • Carle Cancer Center
      • Washington, Illinois, Stati Uniti, 61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46237
        • Franciscan Health Indianapolis
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Stati Uniti, 46219
        • Community Cancer Center East
      • Indianapolis, Indiana, Stati Uniti, 46227
        • Community Cancer Center South
      • Indianapolis, Indiana, Stati Uniti, 46256
        • Community Cancer Center North
      • Kokomo, Indiana, Stati Uniti, 46904
        • Community Howard Regional Health
      • Lafayette, Indiana, Stati Uniti, 47905
        • Franciscan Saint Elizabeth Health - Lafayette East
      • Michigan City, Indiana, Stati Uniti, 46360
        • Woodland Cancer Care Center
      • Mooresville, Indiana, Stati Uniti, 46158
        • Franciscan Health Mooresville
      • Terre Haute, Indiana, Stati Uniti, 47804
        • Union Hospital
    • Iowa
      • Ames, Iowa, Stati Uniti, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Stati Uniti, 50010
        • McFarland Clinic - Ames
      • Bettendorf, Iowa, Stati Uniti, 52722
        • University of Iowa Healthcare Cancer Services Quad Cities
      • Boone, Iowa, Stati Uniti, 50036
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Stati Uniti, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Stati Uniti, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Stati Uniti, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Stati Uniti, 50314
        • Broadlawns Medical Center
      • Des Moines, Iowa, Stati Uniti, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Stati Uniti, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Stati Uniti, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Fort Dodge, Iowa, Stati Uniti, 50501
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Stati Uniti, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Stati Uniti, 50158
        • McFarland Clinic - Marshalltown
      • West Des Moines, Iowa, Stati Uniti, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Hays, Kansas, Stati Uniti, 67601
        • HaysMed
      • Lawrence, Kansas, Stati Uniti, 66044
        • Lawrence Memorial Hospital
      • Olathe, Kansas, Stati Uniti, 66061
        • The University of Kansas Cancer Center - Olathe
      • Salina, Kansas, Stati Uniti, 67401
        • Salina Regional Health Center
      • Topeka, Kansas, Stati Uniti, 66606
        • University of Kansas Health System Saint Francis Campus
      • Westwood, Kansas, Stati Uniti, 66205
        • University of Kansas Hospital-Westwood Cancer Center
      • Wichita, Kansas, Stati Uniti, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Stati Uniti, 67214
        • Cancer Center of Kansas - Wichita
    • Kentucky
      • Bardstown, Kentucky, Stati Uniti, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Lexington, Kentucky, Stati Uniti, 40536
        • University of Kentucky/Markey Cancer Center
      • Lexington, Kentucky, Stati Uniti, 40503
        • Baptist Health Lexington
      • Lexington, Kentucky, Stati Uniti, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • Louisville, Kentucky, Stati Uniti, 40202
        • Norton Hospital Pavilion and Medical Campus
      • Louisville, Kentucky, Stati Uniti, 40241
        • Norton Brownsboro Hospital and Medical Campus
      • Louisville, Kentucky, Stati Uniti, 40217
        • Norton Audubon Hospital and Medical Campus
    • Louisiana
      • Kenner, Louisiana, Stati Uniti, 70065
        • Ochsner Medical Center Kenner
      • New Orleans, Louisiana, Stati Uniti, 70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Augusta, Maine, Stati Uniti, 04330
        • Harold Alfond Center for Cancer Care
      • Bangor, Maine, Stati Uniti, 04401
        • Eastern Maine Medical Center
      • Belfast, Maine, Stati Uniti, 04915
        • MaineHealth Waldo Hospital
      • Biddeford, Maine, Stati Uniti, 04005
        • MaineHealth Maine Medical Center - Biddeford
      • Brewer, Maine, Stati Uniti, 04412
        • Lafayette Family Cancer Center-EMMC
      • Rockport, Maine, Stati Uniti, 04856
        • Penobscot Bay Medical Center
      • Sanford, Maine, Stati Uniti, 04073
        • MaineHealth Cancer Care and IV Therapy - Sanford
      • South Portland, Maine, Stati Uniti, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21244
        • Kaiser Permanente-Woodlawn Medical Center
      • Easton, Maryland, Stati Uniti, 21601
        • University of Maryland Shore Medical Center at Easton
      • Gaithersburg, Maryland, Stati Uniti, 20879
        • Kaiser Permanente-Gaithersburg Medical Center
      • Largo, Maryland, Stati Uniti, 20774
        • Kaiser Permanente - Largo Medical Center
      • Lutherville, Maryland, Stati Uniti, 21093
        • Kaiser Permanente Lutherville - Timonium Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Dana-Farber Cancer Institute
      • Lowell, Massachusetts, Stati Uniti, 01854
        • Lowell General Hospital
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Bay City, Michigan, Stati Uniti, 48706
        • McLaren Cancer Institute-Bay City
      • Bloomfield, Michigan, Stati Uniti, 48302
        • McLaren Cancer Institute-Bloomfield
      • Brighton, Michigan, Stati Uniti, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton, Michigan, Stati Uniti, 48114
        • Trinity Health Medical Center - Brighton
      • Brownstown, Michigan, Stati Uniti, 48183
        • Henry Ford Cancer Institute-Downriver
      • Canton, Michigan, Stati Uniti, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton, Michigan, Stati Uniti, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, Stati Uniti, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea, Michigan, Stati Uniti, 48118
        • Chelsea Hospital
      • Clarkston, Michigan, Stati Uniti, 48346
        • McLaren Cancer Institute-Clarkston
      • Clarkston, Michigan, Stati Uniti, 48346
        • Hematology Oncology Consultants-Clarkston
      • Clarkston, Michigan, Stati Uniti, 48346
        • Newland Medical Associates-Clarkston
      • Clinton Township, Michigan, Stati Uniti, 48038
        • Henry Ford Macomb Hospital-Clinton Township
      • Dearborn, Michigan, Stati Uniti, 48126
        • Henry Ford Medical Center-Fairlane
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, Stati Uniti, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Weisberg Cancer Treatment Center
      • Flint, Michigan, Stati Uniti, 48532
        • McLaren Cancer Institute-Flint
      • Flint, Michigan, Stati Uniti, 48532
        • Singh and Arora Hematology Oncology PC
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Jackson, Michigan, Stati Uniti, 49201
        • Allegiance Health
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • West Michigan Cancer Center
      • Lansing, Michigan, Stati Uniti, 48910
        • Karmanos Cancer Institute at McLaren Greater Lansing
      • Lansing, Michigan, Stati Uniti, 48912
        • University of Michigan Health - Sparrow Lansing
      • Lapeer, Michigan, Stati Uniti, 48446
        • McLaren Cancer Institute-Lapeer Region
      • Livonia, Michigan, Stati Uniti, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Livonia, Michigan, Stati Uniti, 48154
        • Hope Cancer Clinic
      • Mount Clemens, Michigan, Stati Uniti, 48043
        • McLaren Cancer Institute-Macomb
      • Mount Pleasant, Michigan, Stati Uniti, 48858
        • McLaren Cancer Institute-Central Michigan
      • Novi, Michigan, Stati Uniti, 48377
        • Henry Ford Medical Center-Columbus
      • Petoskey, Michigan, Stati Uniti, 49770
        • McLaren Cancer Institute-Northern Michigan
      • Pontiac, Michigan, Stati Uniti, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Pontiac, Michigan, Stati Uniti, 48341
        • Trinity Health IHA Medical Group-Alice Gustafson Center
      • Port Huron, Michigan, Stati Uniti, 48060
        • McLaren-Port Huron
      • Saginaw, Michigan, Stati Uniti, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Stati Uniti, 48601
        • MyMichigan Medical Center Saginaw
      • Tawas City, Michigan, Stati Uniti, 48764
        • MyMichigan Medical Center Tawas
      • Traverse City, Michigan, Stati Uniti, 49684
        • Munson Medical Center
      • West Bloomfield, Michigan, Stati Uniti, 48322
        • Henry Ford West Bloomfield Hospital
      • West Branch, Michigan, Stati Uniti, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, Stati Uniti, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Bemidji, Minnesota, Stati Uniti, 56601
        • Sanford Joe Lueken Cancer Center
      • Burnsville, Minnesota, Stati Uniti, 55337
        • Minnesota Oncology - Burnsville
      • Deer River, Minnesota, Stati Uniti, 56636
        • Essentia Health - Deer River Clinic
      • Duluth, Minnesota, Stati Uniti, 55805
        • Essentia Health Cancer Center
      • Hibbing, Minnesota, Stati Uniti, 55746
        • Essentia Health Hibbing Clinic
      • Maplewood, Minnesota, Stati Uniti, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Stati Uniti, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Stati Uniti, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Stati Uniti, 55454
        • Health Partners Inc
      • Saint Paul, Minnesota, Stati Uniti, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Stati Uniti, 55102
        • United Hospital
      • Sandstone, Minnesota, Stati Uniti, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Stati Uniti, 55792
        • Essentia Health Virginia Clinic
    • Mississippi
      • Grenada, Mississippi, Stati Uniti, 38901
        • Baptist Cancer Center-Grenada
      • New Albany, Mississippi, Stati Uniti, 38652
        • Baptist Memorial Hospital and Cancer Center-Union County
      • Oxford, Mississippi, Stati Uniti, 38655
        • Baptist Memorial Hospital and Cancer Center-Oxford
      • Southhaven, Mississippi, Stati Uniti, 38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Ballwin, Missouri, Stati Uniti, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Cape Girardeau, Missouri, Stati Uniti, 63703
        • Saint Francis Medical Center
      • Columbia, Missouri, Stati Uniti, 65212
        • MU Health - University Hospital/Ellis Fischel Cancer Center
      • Joplin, Missouri, Stati Uniti, 64804
        • Freeman Health System
      • Joplin, Missouri, Stati Uniti, 64804
        • Mercy Hospital Joplin
      • Kansas City, Missouri, Stati Uniti, 64108
        • University Health Truman Medical Center
      • St Louis, Missouri, Stati Uniti, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Stati Uniti, 63141
        • Mercy Hospital Saint Louis
    • Montana
      • Anaconda, Montana, Stati Uniti, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Stati Uniti, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Stati Uniti, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Stati Uniti, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Stati Uniti, 59405
        • Benefis Sletten Cancer Institute
      • Helena, Montana, Stati Uniti, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Stati Uniti, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Stati Uniti, 59804
        • Community Medical Center
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Stati Uniti, 89128
        • OptumCare Cancer Care at MountainView
      • Las Vegas, Nevada, Stati Uniti, 89183
        • OptumCare Cancer Care at Fort Apache
      • Reno, Nevada, Stati Uniti, 89502
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
      • Manchester, New Hampshire, Stati Uniti, 03104
        • Dartmouth Cancer Center - Manchester/ DCC Manchester
      • Nashua, New Hampshire, Stati Uniti, 03063
        • Dartmouth Cancer Center - Nashua
    • New Jersey
      • Hamilton, New Jersey, Stati Uniti, 08690
        • The Cancer Institute of New Jersey Hamilton
      • Morristown, New Jersey, Stati Uniti, 07960
        • Morristown Medical Center
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey
      • Paramus, New Jersey, Stati Uniti, 07652
        • The Valley Hospital - Luckow Pavilion
      • Ridgewood, New Jersey, Stati Uniti, 07450
        • Valley Health System Ridgewood Campus
      • Somerville, New Jersey, Stati Uniti, 08876
        • Robert Wood Johnson University Hospital Somerset
      • Summit, New Jersey, Stati Uniti, 07902
        • Overlook Hospital
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • University of New Mexico Cancer Center
      • Albuquerque, New Mexico, Stati Uniti, 87110
        • Presbyterian Kaseman Hospital
      • Las Cruces, New Mexico, Stati Uniti, 88011
        • Memorial Medical Center-Las Cruces
      • Rio Rancho, New Mexico, Stati Uniti, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Buffalo, New York, Stati Uniti, 14263
        • Roswell Park Cancer Institute
      • Elmira, New York, Stati Uniti, 14905
        • Arnot Ogden Medical Center/Falck Cancer Center
      • Lake Success, New York, Stati Uniti, 11042
        • Northwell Health/Center for Advanced Medicine
      • New York, New York, Stati Uniti, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, Stati Uniti, 14642
        • University of Rochester
      • White Plains, New York, Stati Uniti, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Clinton, North Carolina, Stati Uniti, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Stati Uniti, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Hendersonville, North Carolina, Stati Uniti, 28791
        • Margaret R Pardee Memorial Hospital
      • Jacksonville, North Carolina, Stati Uniti, 28546
        • Southeastern Medical Oncology Center-Jacksonville
      • Kenansville, North Carolina, Stati Uniti, 28349
        • ECU Health Oncology Kenansville
      • Kinston, North Carolina, Stati Uniti, 28501
        • ECU Health Oncology Kinston
      • Pinehurst, North Carolina, Stati Uniti, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
      • Richlands, North Carolina, Stati Uniti, 28574
        • ECU Health Oncology Richlands
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Bismarck, North Dakota, Stati Uniti, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, Stati Uniti, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Stati Uniti, 58122
        • Sanford Broadway Medical Center
      • Grand Forks, North Dakota, Stati Uniti, 58201
        • Altru Cancer Center
    • Ohio
      • Akron, Ohio, Stati Uniti, 44307
        • Cleveland Clinic Akron General
      • Belpre, Ohio, Stati Uniti, 45714
        • Strecker Cancer Center-Belpre
      • Centerville, Ohio, Stati Uniti, 45459
        • Miami Valley Hospital South
      • Centerville, Ohio, Stati Uniti, 45459
        • Dayton Physicians LLC-Miami Valley South
      • Chillicothe, Ohio, Stati Uniti, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Stati Uniti, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, Stati Uniti, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Stati Uniti, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Stati Uniti, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Stati Uniti, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Stati Uniti, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Stati Uniti, 43228
        • Doctors Hospital
      • Columbus, Ohio, Stati Uniti, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Stati Uniti, 43215
        • Grant Medical Center
      • Columbus, Ohio, Stati Uniti, 43222
        • Mount Carmel Health Center West
      • Dayton, Ohio, Stati Uniti, 45409
        • Miami Valley Hospital
      • Delaware, Ohio, Stati Uniti, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Stati Uniti, 43015
        • Grady Memorial Hospital
      • Kettering, Ohio, Stati Uniti, 45409
        • Greater Dayton Cancer Center
      • Lancaster, Ohio, Stati Uniti, 43130
        • Fairfield Medical Center
      • Mansfield, Ohio, Stati Uniti, 44906
        • Cleveland Clinic Cancer Center Mansfield
      • Mansfield, Ohio, Stati Uniti, 44903
        • OhioHealth Mansfield Hospital
      • Marietta, Ohio, Stati Uniti, 45750
        • Marietta Memorial Hospital
      • Marion, Ohio, Stati Uniti, 43302
        • OhioHealth Marion General Hospital
      • Mayfield Heights, Ohio, Stati Uniti, 44124
        • Hillcrest Hospital Cancer Center
      • Mount Vernon, Ohio, Stati Uniti, 43050
        • Knox Community Hospital
      • Newark, Ohio, Stati Uniti, 43055
        • Licking Memorial Hospital
      • Portsmouth, Ohio, Stati Uniti, 45662
        • Southern Ohio Medical Center
      • Sandusky, Ohio, Stati Uniti, 44870
        • North Coast Cancer Care
      • Sylvania, Ohio, Stati Uniti, 43560
        • ProMedica Flower Hospital
      • Warrensville Heights, Ohio, Stati Uniti, 44122
        • South Pointe Hospital
      • West Chester, Ohio, Stati Uniti, 45069
        • University of Cincinnati Cancer Center-West Chester
      • Westerville, Ohio, Stati Uniti, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, Stati Uniti, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Lawton, Oklahoma, Stati Uniti, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, Stati Uniti, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
      • Tulsa, Oklahoma, Stati Uniti, 74133
        • Cancer Treatment Centers of America
    • Oregon
      • Bend, Oregon, Stati Uniti, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Stati Uniti, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Stati Uniti, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Newberg, Oregon, Stati Uniti, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Stati Uniti, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Oregon City, Oregon, Stati Uniti, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Stati Uniti, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Stati Uniti, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Allentown, Pennsylvania, Stati Uniti, 18104
        • Saint Luke's Cancer Center - Allentown
      • Bethlehem, Pennsylvania, Stati Uniti, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Bethlehem, Pennsylvania, Stati Uniti, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Easton, Pennsylvania, Stati Uniti, 18045
        • Saint Luke's Hospital-Anderson Campus
      • Erie, Pennsylvania, Stati Uniti, 16544
        • Saint Vincent Hospital
      • Harrisburg, Pennsylvania, Stati Uniti, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Jefferson Hills, Pennsylvania, Stati Uniti, 15025
        • Jefferson Hospital
      • Monroeville, Pennsylvania, Stati Uniti, 15146
        • Forbes Hospital
      • Natrona Heights, Pennsylvania, Stati Uniti, 15065
        • Allegheny Valley Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15224
        • West Penn Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • UPMC Hillman Cancer Center
      • Quakertown, Pennsylvania, Stati Uniti, 18951
        • Saint Luke's Hospital-Quakertown Campus
      • West Reading, Pennsylvania, Stati Uniti, 19611
        • Reading Hospital
      • Wexford, Pennsylvania, Stati Uniti, 15090
        • Wexford Health and Wellness Pavilion
      • Willow Grove, Pennsylvania, Stati Uniti, 19090
        • Asplundh Cancer Pavilion
    • South Carolina
      • Anderson, South Carolina, Stati Uniti, 29621
        • AnMed Health Cancer Center
      • Beaufort, South Carolina, Stati Uniti, 29902
        • Beaufort Memorial Hospital
      • Boiling Springs, South Carolina, Stati Uniti, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Easley, South Carolina, Stati Uniti, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Stati Uniti, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Stati Uniti, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Stati Uniti, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Stati Uniti, 29601
        • Saint Francis Hospital
      • Greer, South Carolina, Stati Uniti, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Stati Uniti, 29672
        • Prisma Health Cancer Institute - Seneca
      • Spartanburg, South Carolina, Stati Uniti, 29303
        • Spartanburg Medical Center
    • South Dakota
      • Aberdeen, South Dakota, Stati Uniti, 57401
        • Avera Cancer Institute-Aberdeen
      • Sioux Falls, South Dakota, Stati Uniti, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Stati Uniti, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Stati Uniti, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Bristol, Tennessee, Stati Uniti, 37620
        • Bristol Regional Medical Center
      • Collierville, Tennessee, Stati Uniti, 38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Cookeville, Tennessee, Stati Uniti, 38501
        • Cookeville Regional Medical Center
      • Johnson City, Tennessee, Stati Uniti, 37604
        • Wellmont Medical Associates Oncology and Hematology-Johnson City
      • Kingsport, Tennessee, Stati Uniti, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Stati Uniti, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Memphis, Tennessee, Stati Uniti, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Texas
      • Amarillo, Texas, Stati Uniti, 79106
        • The Don and Sybil Harrington Cancer Center
      • Beaumont, Texas, Stati Uniti, 77701
        • Baptist Hospitals of Southeast Texas Cancer Center
      • Conroe, Texas, Stati Uniti, 77384
        • UT MD Anderson - The Woodlands
      • Dallas, Texas, Stati Uniti, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Stati Uniti, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Edinburg, Texas, Stati Uniti, 78539
        • STCC at DHR Health Institute for Research and Development
      • Houston, Texas, Stati Uniti, 77026-1967
        • Lyndon Baines Johnson General Hospital
      • Houston, Texas, Stati Uniti, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, Stati Uniti, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Stati Uniti, 77079
        • UT MD Anderson - West Houston
      • League City, Texas, Stati Uniti, 77573
        • UT MD Anderson - League City
      • Port Arthur, Texas, Stati Uniti, 77642
        • Baptist Regional Cancer Network-Cancer Center of Southeast Texas
      • Sugar Land, Texas, Stati Uniti, 77478
        • UT MD Anderson - Sugar Land
      • Temple, Texas, Stati Uniti, 76508
        • Scott and White Memorial Hospital
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute/University of Utah
    • Vermont
      • Saint Johnsbury, Vermont, Stati Uniti, 05819
        • Dartmouth Cancer Center - North
    • Virginia
      • Bristol, Virginia, Stati Uniti, 24201
        • Ballad Health Cancer Care - Bristol
      • Burke, Virginia, Stati Uniti, 22015
        • Kaiser Permanente-Burke Medical Center
      • Fishersville, Virginia, Stati Uniti, 22939
        • Augusta Health Center for Cancer and Blood Disorders
      • Lynchburg, Virginia, Stati Uniti, 24501
        • Centra Alan B Pearson Regional Cancer Center
      • McLean, Virginia, Stati Uniti, 22102
        • Kaiser Permanente Tysons Corner Medical Center
      • Norton, Virginia, Stati Uniti, 24273
        • Ballad Health Cancer Care - Norton
      • Richmond, Virginia, Stati Uniti, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Stati Uniti, 23229
        • Virginia Cancer Institute
      • Richmond, Virginia, Stati Uniti, 23298
        • VCU Massey Comprehensive Cancer Center
      • South Hill, Virginia, Stati Uniti, 23970
        • VCU Community Memorial Health Center
      • Woodbridge, Virginia, Stati Uniti, 22192
        • Kaiser Permanente-Caton Hill Medical Center
    • Washington
      • Edmonds, Washington, Stati Uniti, 98026
        • Swedish Cancer Institute-Edmonds
      • Issaquah, Washington, Stati Uniti, 98029
        • Swedish Cancer Institute-Issaquah
      • Port Townsend, Washington, Stati Uniti, 98368
        • Jefferson Healthcare
      • Seattle, Washington, Stati Uniti, 98122
        • Swedish Medical Center-First Hill
      • Spokane, Washington, Stati Uniti, 99204
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Spokane, Washington, Stati Uniti, 99218
        • MultiCare Deaconess Cancer and Blood Specialty Center - North
    • West Virginia
      • Charleston, West Virginia, Stati Uniti, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
      • Morgantown, West Virginia, Stati Uniti, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Stati Uniti, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Antigo, Wisconsin, Stati Uniti, 54409
        • Aspirus Cancer Care-Antigo-Volm Cancer Center
      • Appleton, Wisconsin, Stati Uniti, 54911
        • ThedaCare Regional Cancer Center
      • Appleton, Wisconsin, Stati Uniti, 54915
        • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Duluth Clinic Ashland
      • Brookfield, Wisconsin, Stati Uniti, 53045
        • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
      • Eau Claire, Wisconsin, Stati Uniti, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Franklin, Wisconsin, Stati Uniti, 53132
        • Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
      • Green Bay, Wisconsin, Stati Uniti, 54301
        • Bellin Memorial Hospital
      • Janesville, Wisconsin, Stati Uniti, 53548
        • Mercyhealth Hospital and Cancer Center - Janesville
      • Johnson Creek, Wisconsin, Stati Uniti, 53038
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Madison, Wisconsin, Stati Uniti, 53718
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marshfield, Wisconsin, Stati Uniti, 54449
        • Marshfield Medical Center-Marshfield
      • Medford, Wisconsin, Stati Uniti, 54451
        • Aspirus Medford Hospital
      • Minocqua, Wisconsin, Stati Uniti, 54548
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, Stati Uniti, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Stati Uniti, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Stati Uniti, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oshkosh, Wisconsin, Stati Uniti, 54904
        • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
      • Racine, Wisconsin, Stati Uniti, 53405
        • Ascension All Saints Hospital-Spring Street-Racine
      • Rhinelander, Wisconsin, Stati Uniti, 54501
        • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
      • Rice Lake, Wisconsin, Stati Uniti, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, Stati Uniti, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Waukesha, Wisconsin, Stati Uniti, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, Stati Uniti, 53188
        • ProHealth Waukesha Memorial Hospital
      • Wausau, Wisconsin, Stati Uniti, 54401
        • Aspirus Cancer Care-Wausau
      • Wauwatosa, Wisconsin, Stati Uniti, 53226
        • Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
      • Weston, Wisconsin, Stati Uniti, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Stati Uniti, 54494
        • Aspirus Cancer Care - Wisconsin Rapids
    • Wyoming
      • Cheyenne, Wyoming, Stati Uniti, 82001
        • Cheyenne Regional Medical Center-West
      • Cody, Wyoming, Stati Uniti, 82414
        • Billings Clinic-Cody

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines

  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

  • Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial

  • Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible

  • Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1

  • No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass

  • Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)

  • Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)

  • Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)

  • Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)

  • Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)

  • A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:

    • The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
    • A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
    • Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
  • International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results

  • Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  • Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period

Exclusion Criteria:

  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin

  • Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria

  • Documented New York Heart Association (NYHA) class III or IV congestive heart failure

  • Serious or non-healing wound, skin ulcer, or bone fracture

  • History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high

  • Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin

  • Known DPD (dihydro pyrimidine dehydrogenase) deficiency

  • Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)

  • Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization

  • History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening

  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:

    • Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
    • No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible

    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible

    • Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  • Patients with known active tuberculosis (TB) are excluded

  • Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Signs or symptoms of infection within 14 days prior to randomization

  • Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible

  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study

  • The administration of a live, attenuated vaccine within 28 days prior to randomization

  • Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm I (bevacizumab, mFOLFOX6)

Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Altri nomi:
  • 5-Fluracile
  • Fluracil
  • 5 Fluorouracile
  • 5FU
  • 5-Fluoro-2,4(1H, 3H)-pirimidinedione
  • 5-Fluorouracile
  • 5-Fu
  • Accu Site
  • Carac
  • Fluorouracile
  • Fluuracile
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Ancillary studies

Undergo collection of blood samples

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • 1-OHP
  • Dacotin
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diamminocicloesano ossalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • GM 83
  • JM83
  • RP54780

Undergo CT or CT/PET

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Given IV

Altri nomi:
  • Acido folinico

Undergo CT/PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm II (atezolizumab)

Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Ancillary studies

Undergo collection of blood samples

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RO-5541267

Undergo CT or CT/PET

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo CT/PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm III (atezolizumab, bevacizumab, mFOLFOX6)

Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

Ancillary studies

Altri nomi:
  • Valutazione della qualità della vita

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Altri nomi:
  • 5-Fluracile
  • Fluracil
  • 5 Fluorouracile
  • 5FU
  • 5-Fluoro-2,4(1H, 3H)-pirimidinedione
  • 5-Fluorouracile
  • 5-Fu
  • Accu Site
  • Carac
  • Fluorouracile
  • Fluuracile
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Ancillary studies

Undergo collection of blood samples

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RO-5541267

Given IV

Altri nomi:
  • 1-OHP
  • Dacotin
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diamminocicloesano ossalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • GM 83
  • JM83
  • RP54780

Undergo CT or CT/PET

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Given IV

Altri nomi:
  • Acido folinico

Undergo CT/PET

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression free survival (PFS)
Lasso di tempo: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years

The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted.

From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Tasso di PFS
Lasso di tempo: A 12 mesi
A 12 mesi
Overall survival (OS)
Lasso di tempo: The time from randomization to death from any cause, assessed up to 5 years

Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

The time from randomization to death from any cause, assessed up to 5 years
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Lasso di tempo: Up to 5 years

Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment.

Up to 5 years
Incidence of adverse events
Lasso di tempo: Up to 30 days after last cycle

Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population.

Up to 30 days after last cycle
Disease control rate (CR + PR + stable disease [SD])
Lasso di tempo: At 12 months

Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment.

At 12 months
Duration of overall response (CR or PR)
Lasso di tempo: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years

Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
Duration of SD
Lasso di tempo: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years

Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Severity of fatigue
Lasso di tempo: At 16 weeks

Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

At 16 weeks
Physical functioning
Lasso di tempo: At 16 weeks

Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

At 16 weeks
Health utility scores
Lasso di tempo: Up to 5 years

Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire.

Up to 5 years
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Lasso di tempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Lasso di tempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Efficacy dependent on the number of somatic mutations
Lasso di tempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Efficacy in tumors with MLH1 silencing
Lasso di tempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Lasso di tempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years
Development of progression or relapse to treatment in cfDNA
Lasso di tempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Lasso di tempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years
PFS of patients with high levels of diversity
Lasso di tempo: Up to 5 years

Compared to patients with low levels of diversity. Will use the ITT population.

Up to 5 years
Change in T-cell diversity
Lasso di tempo: Baseline to first restaging between immunotherapy arms and the standard of care arm

Will use the ITT population.

Baseline to first restaging between immunotherapy arms and the standard of care arm
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Lasso di tempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Caio Max S Rocha Lima, NRG Oncology

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 gennaio 2018

Completamento primario (Stimato)

1 giugno 2027

Completamento dello studio (Stimato)

1 giugno 2027

Date di iscrizione allo studio

Primo inviato

19 dicembre 2016

Primo inviato che soddisfa i criteri di controllo qualità

19 dicembre 2016

Primo Inserito (Stimato)

20 dicembre 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2016-01961
  • U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2016-01961 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • NRG-GI004/S1610
  • NRG-GI004 (Altro identificatore: CTEP)
  • NRG-GI004 (Altro identificatore: NRG Oncology)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .